Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged Edgewise Therapeutics stock dropped, as Cytokinetics shares got a big boost early Wednesday.
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics.
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, tolerability, and dose-linearity. Phase 2 trial expected to start Q4 2024.
CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q2 2024 CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal? CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing.
7 Biotech Stocks to Boost Your Portfolio to Peak Health With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.
Stocks Mixed Amid Flood Of Economic Data The Nasdaq is up triple digits midday, trading at fresh record highs thanks to Nvidia's post-earnings pop.
Why Cytokinetics (CYTK) Shares Are Falling Cytokinetics shares are trading lower by 15.8% during Thursday's session. The company announced the pricing of a public offering of 9,803,922 shares.
